Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

MedImmune Adds Two Academic Partners

by Lisa M. Jarvis
March 24, 2014 | A version of this story appeared in Volume 92, Issue 12

MedImmune, the biologics arm of AstraZeneca, has added two academic partners to broaden its efforts in oncology. The University of Texas M. D. Anderson Cancer Center, under a three-year pact focused on cancer immunotherapy, will test MedImmune molecules in the clinic with the goal of understanding the right combination of treatments and developing biomarkers to guide their use. In a separate three-year deal, MedImmune will work with the University of Cambridge to use imaging technology to understand and measure biological changes within growing tumors.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.